Revascularization Strategies in Multivessel Coronary Artery Disease

  • Cristiano Giovanni Caputi
  • Fabrizio Ricci
  • Carlo De Innocentiis
  • Raffaele De Caterina
  • Marco ZimarinoEmail author


Multivessel coronary artery disease (MVCAD) is traditionally defined as the presence of a ≥50% diameter stenosis in more than one epicardial vessel. It is documented in 40–60% of patients undergoing coronary angiography and, depending on the clinical presentation, is associated with adverse outcomes compared with single-vessel disease. The management of patients with MVCAD is influenced not only by the extent and severity of disease, but also by the clinical presentation, left ventricular systolic function, and the presence of comorbidities such as diabetes and chronic kidney disease.

In MVCAD, myocardial revascularization can be achieved by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), either on all diseased coronary segments (complete anatomical myocardial revascularization) or on selectively targeted lesions (incomplete myocardial revascularization). Complete revascularization confers a long-term prognostic benefit, but is technically more demanding and is associated with a higher rate of in-hospital events compared with incomplete revascularization. We provide a reappraisal of current knowledge and an account of unresolved issues concerning the completeness of myocardial revascularization, critically reviewing the concept of lesion and myocardial functional evaluation, and highlighting the importance of different clinical settings. For patients with MVCAD, the choice between PCI and CABG should depend not only on the adequacy of myocardial revascularization, but also on coronary anatomy, the ischemic burden, myocardial function, and the presence of comorbidities in specific clinical settings.


  1. 1.
    Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D, Brilakis ES. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol. 2013;62(16):1421–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Zimarino M, Ricci F, Romanello M, Di Nicola M, Corazzini A, De Caterina R. Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: a meta-analysis of randomized and observational studies. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2016;87(1):3–12.CrossRefGoogle Scholar
  3. 3.
    Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.CrossRefGoogle Scholar
  4. 4.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O’Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016;133(11):1135–47.CrossRefPubMedGoogle Scholar
  5. 5.
    Zimarino M, Curzen N, Cicchitti V, De Caterina R. The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. Int J Cardiol. 2013;168(3):1748–57.CrossRefPubMedGoogle Scholar
  6. 6.
    Zimarino M, Gallina S, Di Fulvio M, Di Mauro M, Di Giammarco G, De Caterina R, Calafiore AM. Intraoperative ischemia and long-term events after minimally invasive coronary surgery. Ann Thorac Surg. 2004;78(1):135–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Hannan EL, Racz M, Holmes DR, King SB 3rd, Walford G, Ambrose JA, Sharma S, Katz S, Clark LT, Jones RH. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation. 2006;113(20):2406–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Genereux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Xu K, Parise H, Mehran R, Serruys PW, Stone GW. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (synergy between PCI with taxus and cardiac surgery) score. J Am Coll Cardiol. 2012;59(24):2165–74.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chan PS, Patel MR, Klein LW, Krone RJ, Dehmer GJ, Kennedy K, Nallamothu BK, Weaver WD, Masoudi FA, Rumsfeld JS, Brindis RG, Spertus JA. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306(1):53–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim YH, Park DW, Lee JY, Kim WJ, Yun SC, Ahn JM, Song HG, Oh JH, Park JS, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation. 2011;123(21):2373–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE, COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Mancini GB, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. JACC Cardiovasc Interv. 2014;7(2):195–201.CrossRefPubMedGoogle Scholar
  13. 13.
    Zimarino M, Ausiello A, Contegiacomo G, Riccardi I, Renda G, Di Iorio C, De Caterina R. Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol. 2006;48(1):59–65.CrossRefPubMedGoogle Scholar
  14. 14.
    Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334(26):1703–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, Investigators FS. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.CrossRefPubMedGoogle Scholar
  16. 16.
    Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, Siebert U. Fractional flow reserve versus angiography for multivessel evaluation study I. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122(24):2545–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Carrick D, Behan M, Foo F, Christie J, Hillis WS, Norrie J, Oldroyd KG, Berry C. Usefulness of fractional flow reserve to improve diagnostic efficiency in patients with non-ST elevation myocardial infarction. Am J Cardiol. 2013;111(1):45–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Sels JW, Tonino PA, Siebert U, Fearon WF, Van’t Veer M, De Bruyne B, Pijls NH. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (fractional flow reserve versus angiography for multivessel evaluation) study. JACC Cardiovasc Interv. 2011;4(11):1183–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Kolozsvari R, Galajda Z, Ungvari T, Szabo G, Racz I, Szerafin T, Herzfeld I, Edes I, Peterffy A, Koszegi Z. Various clinical scenarios leading to development of the string sign of the internal thoracic artery after coronary bypass surgery: the role of competitive flow, a case series. J Cardiothorac Surg. 2012;7:12.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Botman CJ, Schonberger J, Koolen S, Penn O, Botman H, Dib N, Eeckhout E, Pijls N. Does stenosis severity of native vessels influence bypass graft patency? A prospective fractional flow reserve-guided study. Ann Thorac Surg. 2007;83(6):2093–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Lima RS, Watson DD, Goode AR, Siadaty MS, Ragosta M, Beller GA, Samady H. Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. J Am Coll Cardiol. 2003;42(1):64–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Zaacks SM, Ali A, Parrillo JE, Barron JT. How well does radionuclide dipyridamole stress testing detect three-vessel coronary artery disease and ischemia in the region supplied by the most stenotic vessel? Clin Nucl Med. 1999;24(1):35–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Melikian N, De Bondt P, Tonino P, De Winter O, Wyffels E, Bartunek J, Heyndrickx GR, Fearon WF, Pijls NH, Wijns W, De Bruyne B. Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC Cardiovasc Interv. 2010;3(3):307–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, Cunningham T, Bezlyak V, Ford I, Dargie HJ, Oldroyd KG. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation. 2009;120(22):2207–13.CrossRefPubMedGoogle Scholar
  25. 25.
    Kirschbaum SW, Springeling T, Boersma E, Moelker A, van der Giessen WJ, Serruys PW, de Feyter PJ, van Geuns RJ. Complete percutaneous revascularization for multivessel disease in patients with impaired left ventricular function: pre- and post-procedural evaluation by cardiac magnetic resonance imaging. JACC Cardiovasc Interv. 2010;3(4):392–400.CrossRefPubMedGoogle Scholar
  26. 26.
    Lockie T, Ishida M, Perera D, Chiribiri A, De Silva K, Kozerke S, Marber M, Nagel E, Rezavi R, Redwood S, Plein S. High-resolution magnetic resonance myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant coronary stenoses as determined by fractional flow reserve. J Am Coll Cardiol. 2011;57(1):70–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordi I, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay M, Mahrous A, Ford I, Tzemos N, Sattar N, Welsh P, Radjenovic A, Oldroyd KG, Berry C. Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. Eur Heart J. 2016;37(13):1044–59.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Greenwood JP, Herzog BA, Brown JM, Everett CC, Nixon J, Bijsterveld P, Maredia N, Motwani M, Dickinson CJ, Ball SG, Plein S. Prognostic value of cardiovascular magnetic resonance and single-photon emission computed tomography in suspected coronary heart disease: long-term follow-up of a prospective, diagnostic accuracy cohort study. Ann Intern Med. 2016.
  30. 30.
    Claessen BE, Dangas GD, Weisz G, Witzenbichler B, Guagliumi G, Mockel M, Brener SJ, Xu K, Henriques JP, Mehran R, Stone GW. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J. 2012;33(6):768–75.CrossRefPubMedGoogle Scholar
  31. 31.
    Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.CrossRefGoogle Scholar
  32. 32.
    Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59(9):857–81.CrossRefPubMedGoogle Scholar
  33. 33.
    Hanratty CG, Koyama Y, Rasmussen HH, Nelson GI, Hansen PS, Ward MR. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization. J Am Coll Cardiol. 2002;40(5):911–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Sgura FA, Bertelli L, Monopoli D, Leuzzi C, Guerri E, Sparta I, Politi L, Aprile A, Amato A, Rossi R, Biondi-Zoccai G, Sangiorgi GM, Modena MG. Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. Circ Cardiovasc Interv. 2010;3(5):491–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG, Investigators P. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Kelly DJ, GP MC, Blackman D, Curzen NP, Dalby M, Greenwood JP, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan JN, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick AH. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2013;8(10):1190–8.Google Scholar
  37. 37.
    Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, Jorgensen E, Pedersen F, Saunamaki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aaroe J, Jensen SE, Raungaard B, Kober L, Investigators D-P. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665–71.CrossRefPubMedGoogle Scholar
  38. 38.
    Henriques JP, Hoebers LP, Ramunddal T, Laanmets P, Eriksen E, Bax M, Ioanes D, Suttorp MJ, Strauss BH, Barbato E, Nijveldt R, van Rossum AC, Marques KM, Elias J, van Dongen IM, Claessen BE, Tijssen JG, van der Schaaf RJ, Investigators ET. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: the EXPLORE trial. J Am Coll Cardiol. 2016;68(15):1622–32.CrossRefPubMedGoogle Scholar
  39. 39.
    Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, American College of Cardiology, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139–228.CrossRefPubMedGoogle Scholar
  40. 40.
    Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.CrossRefPubMedGoogle Scholar
  41. 41.
    Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, Michelet P, Roch A, Kerbaul F, Boyer L. Timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes and clinical outcomes: an updated meta-analysis. JACC Cardiovasc Interv. 2016;9(22):2267–76.CrossRefPubMedGoogle Scholar
  42. 42.
    Zimarino M, Cicchitti V, Genovesi E, Rotondo D, De Caterina R. Isolated troponin increase after percutaneous coronary interventions: does it have prognostic relevance? Atherosclerosis. 2012;221(2):297–302.CrossRefPubMedGoogle Scholar
  43. 43.
    Ajani AE, Waksman R, Zimarino M, Kim HS, Pichard AD, Satler LF, Kent KM, White RL, Pinnow E, Mehran R, Lansky A, Lindsay J. Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials). Am J Cardiol. 2002;89(2):137–44.CrossRefPubMedGoogle Scholar
  44. 44.
    Hannan EL, Wu C, Walford G, Holmes DR, Jones RH, Sharma S, King SB 3rd. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv. 2009;2(1):17–25.CrossRefPubMedGoogle Scholar
  45. 45.
    Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, Moliterno DJ, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol. 2007;49(8):849–54.CrossRefPubMedGoogle Scholar
  46. 46.
    Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA, Van’t Veer M, Pijls NH. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816–21.CrossRefPubMedGoogle Scholar
  47. 47.
    Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, Calcagno S, Ugo F, Boccuzzi G, Fedele F, Mancone M. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J Am Coll Cardiol. 2016;67(3):264–72.CrossRefPubMedGoogle Scholar
  48. 48.
    Puskas JD, Halkos ME, DeRose JJ, Bagiella E, Miller MA, Overbey J, Bonatti J, Srinivas VS, Vesely M, Sutter F, Lynch J, Kirkwood K, Shapiro TA, Boudoulas KD, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff SJ, Zhao D, Gelijns AC, Szeto WY, Weisz G, Argenziano M, Vassiliades T, Liberman H, Matthai W, Ascheim DD. Hybrid coronary revascularization for the treatment of multivessel coronary artery disease: a multicenter observational study. J Am Coll Cardiol. 2016;68(4):356–65.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.CrossRefPubMedGoogle Scholar
  50. 50.
    Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRefGoogle Scholar
  51. 51.
    Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation. 1993;88(5 Pt 1):2426–36.CrossRefPubMedGoogle Scholar
  52. 52.
    Malek LA, Reynolds HR, Forman SA, Vozzi C, Mancini GB, French JK, Dziarmaga M, Renkin JP, Kochman J, Lamas GA, Hochman JS. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: results from the Occluded Artery Trial (OAT). Am Heart J. 2009;157(4):724–32.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med. 2009;122(2):152–61.CrossRefPubMedGoogle Scholar
  54. 54.
    Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation. 2013;127(7):769–81.CrossRefPubMedGoogle Scholar
  55. 55.
    Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.CrossRefPubMedGoogle Scholar
  56. 56.
    Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128(2):141–51.CrossRefPubMedGoogle Scholar
  57. 57.
    Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358(4):331–41.CrossRefPubMedGoogle Scholar
  58. 58.
    Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts – effects on survival over a 15-year period. N Engl J Med. 1996;334(4):216–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, Flather M, ART Investigators. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med. 2016;375:2540–9.CrossRefPubMedGoogle Scholar
  60. 60.
    De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Mobius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Juni P, Fearon WF, FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.CrossRefPubMedGoogle Scholar
  61. 61.
    Jeroudi OM, Alomar ME, Michael TT, El Sabbagh A, Patel VG, Mogabgab O, Fuh E, Sherbet D, Lo N, Roesle M, Rangan BV, Abdullah SM, Hastings JL, Grodin J, Banerjee S, Brilakis ES. Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;84(4):637–43.CrossRefGoogle Scholar
  62. 62.
    Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J. 1993;126(3 Pt 1):561–4.CrossRefPubMedGoogle Scholar
  63. 63.
    Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005;95(9):1088–91.CrossRefPubMedGoogle Scholar
  64. 64.
    Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, Hachamovitch R. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6(3):363–72.CrossRefPubMedGoogle Scholar
  65. 65.
    Tamburino C, Capranzano P, Capodanno D, Dangas G, Zimarino M, Bass TA, Mehran R, Antoniucci D, Colombo A, La Manna A, Di Salvo ME, Stone GW. Percutaneous recanalization of chronic total occlusions: wherein lies the body of proof? Am Heart J. 2013;165(2):133–42.CrossRefPubMedGoogle Scholar
  66. 66.
    Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996;27(3):528–35.CrossRefPubMedGoogle Scholar
  67. 67.
    Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108(12):1527–32.CrossRefPubMedGoogle Scholar
  68. 68.
    Investigators B. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49(15):1600–6.CrossRefGoogle Scholar
  69. 69.
    Group BDS, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRefGoogle Scholar
  70. 70.
    Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ, Ikeno F, King SB 3rd. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ Cardiovasc Interv. 2012;5(2):166–73.CrossRefPubMedGoogle Scholar
  71. 71.
    Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V, FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–84.CrossRefPubMedGoogle Scholar
  72. 72.
    Kurbaan AS, Bowker TJ, Ilsley CD, Sigwart U, Rickards AF, CABRI Investigators. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol. 2001;87(8):947–50; A3.CrossRefPubMedGoogle Scholar
  73. 73.
    Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373(9670):1190–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Mack MJ, Banning AP, Serruys PW, Morice MC, Taeymans Y, Van Nooten G, Possati G, Crea F, Hood KL, Leadley K, Dawkins KD, Kappetein AP. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg. 2011;92(6):2140–6.CrossRefPubMedGoogle Scholar
  75. 75.
    Bangalore S. Applicability of the COURAGE, BARI 2D, and FREEDOM trials to contemporary practice. J Am Coll Cardiol. 2016;68(10):996–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32(22):2748–57.CrossRefPubMedGoogle Scholar
  77. 77.
    Chertow GM, Normand SL, McNeil BJ. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol JASN. 2004;15(9):2462–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Wang ZJ, Zhou YJ, Liu YY, Shi DM, Zhao YX, Guo YH, Cheng WJ, Yu M. Comparison of drug-eluting stents and coronary artery bypass grafting for the treatment of multivessel coronary artery disease in patients with chronic kidney disease. Circ J Off J Jpn Circ Soc. 2009;73(7):1228–34.Google Scholar
  79. 79.
    Chung JW, Park KH, Lee MH, Park KW, Park JS, Kang HJ, Koo BK, Kwon YW, Kim HS. Benefit of complete revascularization in patients with multivessel coronary disease in the drug-eluting stent era. Circ J Off J Jpn Circ Soc. 2012;76(7):1624–30.Google Scholar
  80. 80.
    Seddon M, Curzen N. Coronary revascularisation in chronic kidney disease. Part II: acute coronary syndromes. J Ren Care. 2010;36(Suppl 1):118–26.CrossRefPubMedGoogle Scholar
  81. 81.
    Seddon M, Curzen N. Coronary revascularisation in chronic kidney disease. Part 1: stable coronary artery disease. J Ren Care. 2010;36(Suppl 1):106–17.CrossRefPubMedGoogle Scholar
  82. 82.
    Feldman DN, Minutello RM, Gade CL, Wong SC. Outcomes following immediate (ad hoc) versus staged percutaneous coronary interventions (report from the 2000 to 2001 New York State Angioplasty Registry). Am J Cardiol. 2007;99(4):446–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Calafiore AM, Gallina S, Contini M, Iaco A, Barsotti A, Gaeta F, Zimarino M. Surgical treatment of dilated cardiomyopathy with conventional techniques. Eur J Cardiothorac Surg Off J Eur Assoc Cardiothorac Surg. 1999;16(Suppl 1):S73–8.CrossRefGoogle Scholar
  84. 84.
    Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL, STITCH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA, STITCH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617–25.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STITCH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705–17.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Cristiano Giovanni Caputi
    • 1
  • Fabrizio Ricci
    • 1
  • Carlo De Innocentiis
    • 1
  • Raffaele De Caterina
    • 1
  • Marco Zimarino
    • 1
    Email author
  1. 1.Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University – ChietiChietiItaly

Personalised recommendations